TrialBlood neoplasia2024

Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.

Ulrich Dührsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.